Mdg.Wa

MDG.WA's capital structure is characterized by a debt-to-equity ratio of 0.1, indicating a relatively low level of leverage. The company's liquidity position is assessed as medium, with a current ratio of 2.49, suggesting it has sufficient short-term assets to cover its liabilities, but with no cash and equivalents on hand. The company's operating cash flow is negative at -13,079,000 PLN, and its free cash flow is also negative at -12,583,000 PLN, indicating a cash outflow from operations.

Profitability metrics for MDG.WA are concerning, with a return on equity of -20.84% and a return on assets of -15.2%, both significantly below the industry median for the Advanced Medical Equipment & Technology sector. The company reported a net loss of 16,081,000 PLN and an operating loss of 16,538,000 PLN, reflecting poor operational performance. Gross profit of 20,367,000 PLN is insufficient to cover operating expenses, contributing to the net loss.

MDG.WA's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risk if demand in its primary market fluctuates.

The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The negative operating and free cash flows suggest the company is not generating sufficient cash to fund operations or growth initiatives. The capital expenditure of -139,000 PLN indicates minimal investment in new assets, which may limit future growth potential.

Risk factors for MDG.WA include its negative net cash position after subtracting total debt, which could impact its ability to meet short-term obligations. The company's liquidity risk is moderate, but the absence of cash and equivalents increases vulnerability to cash flow disruptions. The dilution risk is assessed as low, with no significant dilution expected in the near term.

Recent events for MDG.WA include analyst estimates that are uniformly set at 44.70 PLN, with a mean recommendation of 1.50, indicating a generally positive outlook from analysts. However, the company's financial performance and cash flow challenges may affect the realization of these estimates.